ESMO Supporter 2018

Displaying One Session

Hall A1 - Room 15 Poster Discussion session
Date
20.10.2018
Time
15:00 - 16:15
Location
Hall A1 - Room 15
Chairs
  • Hervé Bonnefoi (Bordeaux, FR)
  • Marc Van de Vijver (Amsterdam, NL)
  • Veronique Dieras (Rennes, FR)
Poster Discussion session - Breast cancer, early stage Poster Discussion session

LBA13 - Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Presentation Number
LBA13
Lecture Time
15:00 - 15:00
Speakers
  • Oleg Gluz (Mönchengladbach, DE)
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15

Abstract

Background

Optimal chemotherapy in early TNBC is unclear. ADAPT TN demonstrated higher pCR (ypT0/is/ypN0/(primary endpoint): 46% vs. 29%) and better safety for nab-paclitaxel/carboplatin(nab-pac/carbo) vs nab-paclitaxel/gemcitabine (nab-pac/gem). Planned translational analysis (e.g. expression of 119 genes (nCounter®)) revealed a strong positive predictive impact of basal-like subtype, Ki‑67, HER2-score and immune markers (PDL1, PD1) on pCR.

Methods

Patients with centrally confirmed TNBC (ER/PR<1%, HER2-, cT1c-cT4c, cN0/+) were randomized to neoadjuvant 4x nab-pac/gem 125 mg/m2/1000 mg/m2 d1,8 q3w (A) vs. 4x nab-pac/carbo 125 mg/m2/ AUC2 day 1/8 3-weekly (q3w) (B). Adjuvant anthracycline-based chemotherapy CHT/4xEC was optional in patients with pCR at investigator decison. Per-protocol (interim) survival analysis was performed after 3y median follow-up (FU).

Results

336 patients (median age 50y) were enrolled (48 centers, arms A/B: n=182/154). At baseline, 63% had cT2-4c tumors; 26.2% were cN+. Attainment of pCR was highly favorable for EFS (3y EFS: 92% vs. 71%, p<0.001) and OS (3y OS: 99.1% vs. 81.6%, p<0.001); 3y EFS was similar in Arm A vs. B (77.6% vs 80.8%, p=0.48); 3y OS was numerically higher in Arm B (84.7% vs. 92.2%, p=0.08).

Further (adjuvant) CHT was omitted in n=48 pCR patients (41%, n=26/22 A/B). Differences in EFS and OS by CHT were not significant (3y EFS: 97.0% with CHT vs. 85.5% without CHT, p=.16; 3y OS: 100% with CHT vs. 97.8 without CHT, p=.08).

Among immune/proliferation markers and clinical factors with significant (or borderline significant) association with pCR overall, only PD1 and clinical factors cN and cT were significantly associated with EFS in univariable analysis.

Conclusions

ADAPT TN confirms the strong prognostic impact of pCR in TNBC. However, the higher pCR rate favoring carbo was not reflected in a significant EFS or OS advantage for carbo-containing CHT in our collective after 36 months FU. Nonetheless, a more detailed evaluation of carbo-based de-escalated chemotherapy in selected patients could be a viable approach in TNBC.

Clinical trial identification

NCT01815242

Collapse
Poster Discussion session - Breast cancer, early stage Poster Discussion session

LBA14_PR - The HOBOE-2 multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing Triptorelin plus either Tamoxifen or Letrozole or Letrozole + Zoledronic acid.

Presentation Number
LBA14_PR
Lecture Time
15:00 - 15:00
Speakers
  • Francesco Perrone (Napoli, IT)
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15

Abstract

Background

Role of aromatase inhibitors and zoledronic acid as adjuvant treatment of premenopausal endocrine-responsive breast cancer patients is debated. Letrozole has never been tested in this clinical setting.

Methods

Following surgery and eventual neoadjuvant or adjuvant chemotherapy, premenopausal patients (last menses within 1 yr) were randomly assigned 1:1:1 to Triptorelin 3.75 mg every 4 weeks plus either Tamoxifen 20 mg/die (T), or Letrozole 2.5 mg/die (L) or Zoledronic acid 4mg iv every 6 months + Letrozole 2.5 mg/die (ZL), for 5 years. The primary end-point was disease-free survival (DFS) including locoregional or distant recurrence, second breast or non-breast invasive cancer and death without cancer as event. Analysis was based on intention-to-treatment. Pairwise comparisons (with Bonferroni-Holm correction) were allowed if overall test was statistically significant. The IDMC suggested final analysis be done after 5yrs median follow-up, independently of number of events.

Results

From March 2004 to August 2015, 1065 patients were randomized (T: 354, L:356, ZL: 355) in 16 centres in Italy. Median age was 45; 68% had a pT1 tumor; 55% had negative nodes; 63% had received chemotherapy. After 65 months median follow-up, there were 58, 44, and 32 DFS events and 5 yrs DFS probability was 0.85, 0.93 and 0.93 in the T, L and ZL arms, respectively (P=0.008). Pairwise comparison was statistically significant for ZL vs T (HR 0.52, 95% CI 0.34-0.80, P=0.003) but not for L vs T (HR 0.72, 95% CI 0.48-1.07, P=0.06) and ZL vs L (HR 0.70, 95% CI 0.44-1.12, P=0.22). ZL was more effective than T in all subgroups, but for HER2-positive cases (interaction P=0.002). Twenty-six (7%) patients with T, 26 (7%) with L and 59 (17%) with ZL stopped assigned treatment before 5 yrs due to toxicity or refusal. Grade 3-4 side-effects were reported in 4%, 7% and 9% of patients with T, L and ZL, respectively; there were 4 cases of osteonecrosis of the jaw in the ZL arm.

Conclusions

HOBOE shows that, in premenopausal early breast cancer patients, the ZL+triptorelin combination is more effective than T+triptorelin in terms of DFS.

Clinical trial identification

clinicaltrials.gov: NCT00412022.

Editorial Acknowledgement

No editorial assistance

Collapse
Poster Discussion session - Breast cancer, early stage Poster Discussion session

188PD - Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)

Presentation Number
188PD
Lecture Time
15:00 - 15:00
Speakers
  • Michael Untch (Berlin, DE)
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15

Abstract

Background

The GeparSepto trial demonstrated a higher pathological complete response (pCR) rate after weekly nP compared to P followed by epirubicin (E) plus cyclophosphamide (C) as neoadjuvant treatment for early BC. We report an updated analysis of the key secondary endpoints.

Methods

Patients (pts) with histologically confirmed primary BC were randomized 1:1 to either weekly nP 150mg/m2 (nP150) for 12 weeks, after study amendment 125mg/m2 (nP125) or weekly P 80mg/m2 for 12 weeks followed by E 90mg/m2 plus C 600mg/m2 q3w for 4 cycles. Pts with HER2+ BC received concurrent trastuzumab (Herceprin®) 6mg/kg (loading (LD) dose 8mg/kg) and pertuzumab 420mg (LD 840mg) q3w. Primary objective was pCR (ypT0 ypN0). Key secondary objectives were disease-free survival (DFS), overall survival (OS), peripheral sensory neuropathy (PSN). DFS rates before and after nP dose reduction are reported.

Results

Between 7/2012 and 12/2013, a total of 1229 pts were randomized, 1206 started treatment (nP n = 606, P n = 600), 455 pts started therapy before and 751 after the amendment. After a median follow-up of 49.7 months (range 0.5-64.0) 248 DFS-events (nP n = 103, P n = 145) and 137 deaths (nP n = 63, P n = 74) were reported. Overall, pts with nP had a significantly longer DFS compared to P (HR 0.67 [95%CI 0.52-0.87], p = 0.002); OS did not differ between the two arms. The 3-year DFS rates were nP150 85.5% vs P 75.2% (HR 0.66 [95%CI 0.46-0.96], p = 0.026) for pts treated before and nP125 88.2% vs P 84.1% (HR 0.68 [95%CI 0.48-0.97], p = 0.032) for those after the amendment. Pts treated with nP150 compared to pts with nP125 had less predominant HER2+ BC and Ki67>20% (24.2% vs 38.1%; 60.4% vs 74.3%, respectively), while ER/PR-negativity was more frequent (36.3 vs 29.0%) (Furlanetto et al. Breast Cancer Res Treat. 2017). PSN resolutions in the two cohorts will be presented at the meeting.

Conclusions

The nP dose reduction did not compromise the DFS compared to P. The lower DFS rates with nP150 compared to nP125 can be explained by the different risk profile of the two cohorts.

Clinical trial identification

NCT01583426.

Legal entity responsible for the study

GBG Forschungs GmbH.

Funding

The trial was financially supported by Celgene and Roche.

Disclosure

C. Jackisch: Grants: Celgene, outside the submitted work. A. Schneeweiss: Personal fees: Roche, Grants and personal fees: Celgene; Personal fees outside the submitted work: Pfizer, AstraZeneca, B. Aktas: Personal fees and non-financial support: Roche, Celgene; Personal fees from Novartis, Pfizer, outside the submitted work. C. Denkert: Personal fees: Teva, Novartis, Pfizer, Roche, Amgen, MSD Oncology; Other: Sividon Diagnostics, outside the submitted work. S. Kümmel: Consulting or advisory role: Amgen, Celgene, Roche, Novartis, Astra Zeneca, MSD, Somatec. P.A. Fasching: Personal fees: Celgene, during the conduct of the study; Grants and personal fees: Novartis; Personal fees: Pfizer, Roche, Teva, outside the submitted work. C. Hanusch: Personal fees:Celgene, Pfizer, Roche, Lilly, Novartis, outside the submitted work. G. von Minckwitz: Research funding (institute): Pfizer, Sanofi, Amgen, Roche, Novartis, Celgene, Teva, AstraZeneca, Myriad Genetics, Abbvie, Vifor Pharma. S. Loibl: Grants (institution): AbbVie, Amgen, AstraZeneca, Celgene, Novartis, Pfizer, Roche, Teva, Vifor during the conduct of the study as well as outside the submitted work. All other authors have declared no conflicts of interest.

Collapse
Poster Discussion session - Breast cancer, early stage Poster Discussion session

Invited Discussant LBA13, LBA14_PR and 188PD

Lecture Time
15:00 - 15:15
Speakers
  • Hervé Bonnefoi (Bordeaux, FR)
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15
Poster Discussion session - Breast cancer, early stage Poster Discussion session

Q&A led by Discussant

Lecture Time
15:15 - 15:25
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15
Poster Discussion session - Breast cancer, early stage Poster Discussion session

189PD - Tumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04)

Presentation Number
189PD
Lecture Time
15:25 - 15:25
Speakers
  • Annelot G. Van Rossum (Amsterdam, NL)
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15

Abstract

Background

Increased tumor infiltrating lymphocytes (TILs) predict response to neoadjuvant chemotherapy and is also associated with favorable survival in triple negative breast cancer (TNBC). However, it is unknown whether the presence of TILs can be used as a biomarker to select patients for a specific type of chemotherapy, such as the addition of a taxane to anthracycline-based adjuvant chemotherapy. The primary objective of the MATADOR trial (ISRCTN61893718) was to test whether gene expression profiling can be used to select patients who will benefit from the addition of docetaxel.

Methods

Patients were randomized between 6 cycles adjuvant docetaxel-doxorubicin-cyclophosphamide (T75A50C500) and 6 cycles dose-dense AC (ddA60C600). The primary endpoint was recurrence free survival (RFS). RNA-sequencing data were obtained from 591 (482 ER-positive, 91 TNBC and 18 HER2-positive) of the 664 patients enrolled in this multicenter trial. Gene set enrichment analysis (GSEA) was done using the median expression of the 50 hallmark gene sets. Additionally, TILs were scored according to the guidelines of the International TILs working group.

Results

With 7 years follow up, we observed 102 RFS events. Due to the overall low number of events our analyses did not reveal a robust predictive gene expression profile. However, GSEA of the hallmark gene sets showed significant interaction between immune-related pathways (such as interferon-alpha, regulatory T cells, T cells) and the addition of docetaxel in the exploratory subgroup analysis with TNBC. In subsequent analysis of TILs, TNBC patients were classified as TIL high (≥20%) or TIL low (<20%) according to the median. A significant interaction between TILs and treatment was observed for RFS (adjusted p = 0.022) with a better RFS of TIL high patients versus TIL low patients after TAC treatment (hazard ratio 0.15, confidence interval 0.03-0.69), and not after ddAC.

Conclusions

In our prospective randomized clinical trial we observed a significant benefit from adding docetaxel to AC in patients with high TIL tumours, while this benefit was not observed in patients with low TIL tumours.

Clinical trial identification

ISRCTN61893718 - date assigned: 20/12/2005.

Legal entity responsible for the study

Netherlands Cancer Institute.

Funding

Unrestricted research grants from Sanofi and Amgen.

Disclosure

H.M. Oosterkamp: Unrestricted institutional research grant: Sanofi and Amgen to conduct the MATADOR study (ISRCTN61893718); Advisory board member: Roche, Pfizer and Novartis; Research support funding: Roche. M. Kok: Advisory board member: BMS; Institutional research support funding: Roche and BMS. S.C. Linn: Unrestricted institutional research grant: Sanofi and Amgen to conduct the MATADOR study (ISRCTN61893718); Advisory board member: AstraZeneca, Cergentis, Novartis, Pfizer, Roche, and Sanofi; Institutional research support funding: Amgen, AstraZeneca, Genentech, Roche, Sanofi and Tesaro. All other authors have declared no conflicts of interest.

Collapse
Poster Discussion session - Breast cancer, early stage Poster Discussion session

190PD - Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies

Presentation Number
190PD
Lecture Time
15:25 - 15:25
Speakers
  • Giampaolo Bianchini (Milan, IT)
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15

Abstract

Background

In the NeoSphere trial, we assessed research-based PAM50 subtype predictors at baseline in all patients (pts), and at surgery (SX) in pts with residual disease (RD) to investigate the changes after treatment and the association with pCR and distant event free survival (DEFS).

Methods

417 HER2+ pts were randomized to neoadjuvant TD, TPD, TP or PD (T=trastuzumab, P=pertuzumab, D=docetaxel), and received FAC/FEC and T after SX. 296 pts had RD. We assessed the intrinsic subtypes, ROR-P and ROR-S in 350 (83.9%) and 191 (64.5%) pts at baseline and SX respectively (166 paired samples). We evaluated the association with pCR and DEFS in the overall population and by ER status (161 (46.0%) ER+; 189 (54%) ER-).

Results

The intrinsic subtype distribution was different by ER status. After adjustment for ER, no significant association with pCR was found. None of the baseline biomarkers was associated with DEFS in the overall population. In ER+, Her2-enriched (Her2E) subtype was associated with worst prognosis (HR 3.00 [1.10-8.22]; p = 0.032). Higher ROR-P and ROR-S were significantly associated with higher risk of recurrence in ER+ only (test for interaction p = 0.035 and p = 0.012, respectively). At SX, there was a significant increase in LumA and a decrease in Her2E and LumB subtypes. ROR scores also decreased. In ER+, post-treatment Her2E (HR 7.50 [1.86-30.1]; p = 0.044) and LumB (HR 3.12 [1.03-9.94]; p = 0.004) subtypes were associated with worst outcome than LumA. ROR-S and ROR-P were associated with outcome in ER+ tumors only (significant test for interaction). Compared to low-ROR-S group, high (HR 10.5 [2.79-39.3]; p = 0.0005) and median (HR 3.52 [1.11-11.4]; p = 0.032) groups had higher recurrence risk. Five year-DEFS was 94%, 78% and 50% in the low, median and high ROR-S groups, respectively. In paired samples, the post-treatment biomarker assessment was more informative than at baseline.

Conclusions

In the NeoSphere study, PAM50 provides different prognostic information in ER+ and ER- tumors. Pre-treatment biomarkers were less informative than post-treatment, reflecting their dynamic modulation. In ER+ tumors with RD, PAM50-derived scores assessed on surgical samples might identify patients who need treatment escalation. This warrants independent validation.

Legal entity responsible for the study

Fondazione Michelangelo.

Funding

Has not received any funding.

Disclosure

G. Bianchini: Consultant or advisory board member: Roche, EISAI, Pfizer, AstraZeneca, Novartis, MSD, Lilly, Amgen. C.M. Perou: Equity stock holder, consultant, and Board of Director Member: BioClassifier LLC; Listed an inventor on patent applications on the Breast PAM50 assay. A. Prat: Consultancy: Pfizer, Eli Lilly, Novartis, Nanostring Technologies Research funding Novartis, Nanostring Technologies; Scientific advisory board: Oncolytics Biotech. L. Gianni: Consultant or advisor board member: Roche, Pfizer, Boehringer Ingelheim, Celgene, Tahio Pharmaceutical, Synthon, AstraZeneca, Genomic Health, Merck Sharp & Dohme, Synaffix, Eli Lilly, Odonate Therapeutics, Sandoz, Onkaido, Oncolytics Biotech, ADC Therapeutics, Seattle Genetics. All other authors have declared no conflicts of interest.

Collapse
Poster Discussion session - Breast cancer, early stage Poster Discussion session

Invited Discussant 189PD and 190PD

Lecture Time
15:25 - 15:40
Speakers
  • Marc Van de Vijver (Amsterdam, NL)
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15
Poster Discussion session - Breast cancer, early stage Poster Discussion session

Q&A led by Discussant

Lecture Time
15:40 - 15:50
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15
Poster Discussion session - Breast cancer, early stage Poster Discussion session

191PD_PR - 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Presentation Number
191PD_PR
Lecture Time
15:50 - 15:50
Speakers
  • Pier Franco Conte (Padova, IT)
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15

Abstract

Background

In the ShortHER trial, 1254 HER2+ early breast cancer patients were randomized to 9 weeks versus 1 year trastuzumab. At 6 years median follow up, non inferiority could not be claimed according to the frequentistic approach (HR 1.13; 90% CI 0.89;1.42) with the upper limit of CI crossing the non inferiority margin set at 1.29. However, based on the pre-planned Bayesian analysis, the probability that the short arm is not inferior to the long one was 80%. Moreover, G >/= 2 cardiac events were 82 in the long and 27 in the short arm (RR 0.33, 95% CI 0.22 to 0.55). It is therefore of interest to identify subgroups of patients for whom, based on the risk/benefit ratio, a shorter treatment might be an option

Methods

At multivariate analysis, pathologic tumor size and nodal status were independent prognostic parameter for Disease-Free Survival (DFS) and three prognostic groups could be identified: low risk (pT </= 2cm and N0), intermediate risk (pT </= 2cm and any N category or pT > 2cm and N 0-3) and high risk (pT > 2cm and N 4+).

Results

The low, intermediate and high risk groups included 37.5%, 51.9% and 10.5% of the patient population, respectively. The 5 year DFS and G>/=2 cardiac events in the long and short arms according to the prognostic group are summarized below:

5 year DFS

Hazard Ratio(95% CI)
Long arm Short arm
Low risk 91% 92% 0.96 (0.56-1.66)
Intermediate risk 87% 86% 1.05 (0.71-1.54)
High risk 80% 60% 1.94 (1.07-3.53)
G>/=2 cardiac events Relative Risk (95% CI)
Low risk 14.6% 5.1% 2.85 (1.51-5.36)
Intermediate risk 11.6% 3.9% 2.9 (1.57-5.35)
High risk 14.1 3.3 4.22 (0.96-18.5)

Conclusions

Subgroups analysis of the ShortHER trial allows to identify patients at low and intermediate risk of relapse. This population includes 89% of the patients and the 5 year DFS is not different in the two treatment arms (89% long, 88% short; HR 1.02, 95% CI 0.78-1.33); on the contrary, the risk of cardiac events is significantly higher in the long arm (12.8% vs 4.5%; RR 2.88, 95% CI 1.85-4.47). These results may contribute to better define the risk/benefit ratio of 1 year adjuvant trastuzumab.

Clinical trial identification

EUDRACT number: 2007-004326-25

NCI ClinicalTrials.gov number: NCT00629278

Collapse
Poster Discussion session - Breast cancer, early stage Poster Discussion session

192PD - Randomized Trial of Lisinopril or Carvedilol for the Prevention of Cardiotoxicity in Patients with Early Stage HER2-Positive Breast Cancer Receiving Trastuzumab

Presentation Number
192PD
Lecture Time
15:50 - 15:50
Speakers
  • Pamela N. Munster (San Francisco, US)
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15

Abstract

Background

Trastuzumab is an integral part of therapy for patients with HER2-positive breast cancer. Yet, cardiac side effects, particularly in patients who receive anthracyclines require frequent monitoring and result in dose interruptions and discontinuation of trastuzumab. Prophylactic use of angiotensin converting enzyme inhibitors or beta blockers may prevent cardiotoxicity associated with chemotherapy and trastuzumab.

Methods

In a large prospective double-blind, placebo-controlled trial, the rates of pre-specified cardiotoxicity and trastuzumab interruptions were evaluated in patients with early stage HER2 positive breast cancer treated with one year of trastuzumab. Patients were randomized to simultaneously receive either the ACE inhibitor, lisinopril, or beta-blocker, carvedilol, or placebo and were stratified by anthracycline use.

Results

The study included 468 eligible patients (median age:51, BMI:27 kg/m2, baseline systolic BP: 126mmHg and LVEF: 63 ± 6.29%) from 127 community-based practices. Both interventions reduced trastuzumab interruptions (p = 0.01). For patients receiving an anthracycline, cardiac event rates were higher in the placebo group (47%), compared to lisinopril (37%), and carvedilol (31%). Interruptions of trastuzumab were required in 23% patients on lisinopril and 20% on carvedilol compared to 40% on placebo (p = 0.007). Changes in LVEF from baseline (least square means, SE) were significantly reduced with both carvedilol (-4.5 (0.8), p = 0.008, and lisinopril (-4.0 (0.8), p = 0.002) than placebo, (-7.7 (0.8). Cardiotoxicity-free survival was longer on both carvedilol (hazard ratio 0.49, 95% confidence intervals 0.27, 0.89, p = 0.009) or lisinopril (HR 0.53, CI 0.30, 0.94, p = 0.015). Cardiac events for patients treated with non-anthracycline containing regimens were similar for all groups with no difference in number of trastuzumab interruptions.

Conclusions

Both lisinopril and carvedilol prevented cardiotoxicity in patients with HER2-positive breast cancer treated with trastuzumab and anthracyclines. The use of lisinopril or carvedilol should be considered to offset cardiac events and to minimize interruptions of trastuzumab.

Clinical trial identification

NCT01009918.

Legal entity responsible for the study

National Cancer Institute, Community Oncology and Prevention Trials Research Group, Rockville, MD.

Funding

National Cancer Institute, Community Oncology and Prevention Trials Research Group, Rockville, MD.

Disclosure

All authors have declared no conflicts of interest.

Collapse
Poster Discussion session - Breast cancer, early stage Poster Discussion session

Invited Discussant 191PD and 192PD

Lecture Time
15:50 - 16:05
Speakers
  • Veronique Dieras (Rennes, FR)
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15
Poster Discussion session - Breast cancer, early stage Poster Discussion session

Q&A led by Discussant

Lecture Time
16:05 - 16:15
Location
Hall A1 - Room 15, ICM München, Munich, Germany
Date
20.10.2018
Time
15:00 - 16:15